胸腺肽治疗重症肺炎合并脓毒血症的临床疗效分析

Analysis of clinical effect by thymosin in the treatment of severe pneumonia complicated with septicopyemia

目的探讨胸腺肽对于重症肺炎合并脓毒血症患者的临床治疗效果。方法 70例重症肺炎合并脓毒血症患者按照随机数字表法分为实验组和对照组,各35例。对照组患者给予常规综合治疗,实验组患者在此基础上给予胸腺肽治疗,比较两组患者临床疗效、各项转归时间以及治疗后各项检测指标变化情况。结果实验组患者显效率97.14%显著高于对照组80.00%,差异具有统计学意义(P<0.05);实验组患者机械通气停用时间、血管活性药物停用时间、休克逆转时间均显著短于对照组[(84.17±20.07)h VS(141.76±22.48)h、(3.18±1.16)d VS(6.37±1.73)d、(80.75±22.57)h VS(124.49±25.84)h],差异具有统计学意义(P<0.05);实验组患者治疗后呼吸频率(RR)、心率(HR)、白细胞计数(WBC)、降钙素原(PCT)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均显著低于对照组[(18.06±1.17)次/min VS(20.33±1.75)次/min、(72.44±7.13)次/min VS(80.34±7.46)次/min、(7.51±1.11)×109/L VS(9.79±1.38)×109/L、(1.19±0.08)ng/L VS(1.49±0.20)ng/L、(122.74±15.58)ng/L VS(153.08±17.62)ng/L、(7.99±0.44)ng/L VS(9.18±0.61)ng/L],差异具有统计学意义(P<0.05)。结论胸腺肽能够有效提高重症肺炎合并脓毒血症的临床疗效,缩短转归时间,降低PCT、IL-6、TNF-α水平,临床效果显著,价值较高。

Objective To investigate clinical effect by thymosin in the treatment of severe pneumonia complicated with septicopyemia. Methods A total of severe pneumonia complicated with septicopyemia patients were divided by random number table into experimental and control group, with 35 cases in each group. The control group received conventional comprehensive therapy, and the experimental group received additional thymosin to therapy in the control group for treatment. Comparison was made on clinical effects, prognosis time of index, and changes in detection index after treatment between the two groups. Results The experimental group had obviously higher excellent effective rate as 97.14% than 80.00% in the control group, and their difference had statistical significance（P〈0.05）. The experimental group had all much shorter mechanical ventilation withdrawal time, vasoactive agent withdrawal time and shock reversal time than the control group [（84.17±20.07） h VS（141.76±22.48） h,（3.18±1.16） d VS（6.37±1.73） d,（80.75±22.57） h VS（124.49±25.84） h], and the difference had statistical significance（P〈0.05）. The experimental group had obviously lower respiratory rate（RR）, heart rate（HR）, white blood cell count（WBC）, procalcitonin（PCT）, interleukin-6（IL-6）, and tumor necrosis factor-α（TNF-α） than the control group [（18.06±1.17） times/min VS（20.33±1.75） times/min,（72.44±7.13） beats/min VS（80.34±7.46） beats/min,（7.51±1.11）×10^9/L VS（9.79±1.38）×10^9/L,（1.19±0.08） ng/L VS（1.49±0.20） ng/L,（122.74±15.58） ng/L VS（153.08±17.62） ng/L,（7.99±0.44） ng/L VS（9.18±0.61） ng/L], and their difference had statistical significance（P〈0.05）. Conclusion Thymosin can effectively improve clinical effect for severe pneumonia complicated with septicopyemia patients. It can shorten prognosis time, lower PCT, IL-6, TNF-α levels, along with excellent clinical effect and high value.